Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Apatinib+Ifosfamide and Etoposide (IE) Versus IE Alone for Relapsed or Refractory Osteosarcoma: a Real-world Study in Two Centers in China

NCT04690231 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT04690231
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04690231 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Apatinib+Ifosfamide and Etoposide (IE) Versus IE Alone for Relapsed or Refractory Osteosarcoma: a Real-world Study in Two Centers in China
Lead sponsor
Peking University People's Hospital
Phase
Not applicable
Overall status
Completed
Start date
December 1, 2020
Completion date
June 1, 2021
Enrollment
79 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

effect of drug, secondary resistance, toxicity, drug